Dextropropoxyphene
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
flavoxate
Vasicoselective antimuscarinic (similar properties to oxybutynin) · Urological Antispasmodic
Vasicoselective antimuscarinic (similar properties to oxybutynin)Urological Antispasmodic
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
6 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- DextropropoxypheneSevereDatabaseDDInter
- Potassium ChlorideSevereDatabaseDDInter
- Potassium CitrateSevereDatabaseDDInter
- Sodium OxybateSevereDatabaseDDInter
Mechanism
Flavoxate possesses properties similar to oxybutynin, acting as an antimuscarinic to relieve urinary symptoms like frequency, urgency, and dysuria.
Indications
Urinary frequency associated with lower urinary tract infectionUrgency associated with lower urinary tract infectionDysuria associated with lower urinary tract infection
Dosing
- Adult
- 200 mg tab, 1 tab TDS
Drug interactions
Potassium Chloride
Severe
Database
Clinical effect not specified
Source: DDInter
Potassium Citrate
Severe
Database
Clinical effect not specified
Source: DDInter
Sodium Oxybate
Severe
Database
Clinical effect not specified
Source: DDInter
Topiramate
Severe
Database
Clinical effect not specified
Source: DDInter
Zonisamide
Severe
Database
Clinical effect not specified
Source: DDInter
Alcohol
Moderate
Database
Increased sedation, dizziness, and impaired psychomotor function.
Advise patients to avoid or limit alcohol consumption while taking flavoxate.
Anticholinergics (e.g., Atropine, Dicyclomine, Hyoscine)
Moderate
Database
Increased risk of anticholinergic side effects such as dry mouth, blurred vision, constipation, urinary retention, tachycardia, and CNS effects (confusion, delirium), especially in elderly patients.
Monitor patients for increased anticholinergic side effects. Consider dose reduction of one or both drugs or choose an alternative if severe symptoms occur. Use with caution in elderly patients.
Benzodiazepines (e.g., Diazepam, Lorazepam)
Moderate
Database
Increased sedation, dizziness, and impaired psychomotor function.
Monitor for increased CNS depression. Advise patients against driving or operating heavy machinery. Consider dose reduction of one or both drugs if significant sedation occurs.
Monoamine Oxidase Inhibitors (maois) (e.g., Phenelzine, Selegiline)
Moderate
Database
Increased risk of anticholinergic side effects. While not a direct contraindication, caution is advised due to the complex pharmacology of MAOIs.
Use with caution. Monitor closely for anticholinergic side effects and any unusual CNS symptoms. Consider alternative agents if possible.
Opioid Analgesics (e.g., Morphine, Codeine, Tramadol)
Moderate
Database
Increased risk of severe constipation, paralytic ileus, and enhanced CNS depression (sedation, dizziness).
Monitor for severe constipation and CNS depression. Consider prophylactic laxatives if co-administered. Adjust doses of one or both drugs if necessary. Use with caution.
Phenothiazines (e.g., Chlorpromazine, Prochlorperazine)
Moderate
Database
Increased risk of anticholinergic side effects such as dry mouth, blurred vision, constipation, and urinary retention. May also increase risk of CNS depression.
Monitor for enhanced anticholinergic and CNS depressant effects. Adjust doses or consider alternative agents if symptoms are problematic.
Related guidelines
Ask House about flavoxate
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team